Research analysts at Credit Suisse boosted their price target on shares of Myriad Genetics (NASDAQ:MYGN) from $20.00 to $22.00 in a report released on Monday, Analyst Ratings Network.com reports. The firm currently has an “underperform” rating on the stock. Credit Suisse’s price objective indicates a potential downside of 18.28% from the stock’s previous close.
Shares of Myriad Genetics (NASDAQ:MYGN) traded up 1.24% during mid-day trading on Monday, hitting $26.92. 1,975,418 shares of the company’s stock traded hands. Myriad Genetics has a 52-week low of $22.20 and a 52-week high of $38.27. The stock’s 50-day moving average is $24. and its 200-day moving average is $28.19. The company has a market cap of $2.166 billion and a price-to-earnings ratio of 15.02.
Myriad Genetics (NASDAQ:MYGN) last announced its earnings results on Tuesday, November 5th. The company reported $0.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.46 by $0.22. The company had revenue of $202.50 million for the quarter, compared to the consensus estimate of $167.64 million. During the same quarter in the prior year, the company posted $0.36 earnings per share. The company’s quarterly revenue was up 51.8% on a year-over-year basis. On average, analysts predict that Myriad Genetics will post $2.01 earnings per share for the current fiscal year.
Several other analysts have also recently commented on the stock. Analysts at Jefferies Group raised their price target on shares of Myriad Genetics from $24.00 to $25.00 in a research note to investors on Wednesday, November 6th. They now have a “hold” rating on the stock. Separately, analysts at Ladenburg Thalmann raised their price target on shares of Myriad Genetics from $28.00 to $29.65 in a research note to investors on Wednesday, November 6th. They now have a “buy” rating on the stock. Three investment analysts have rated the stock with a sell rating, nine have issued a hold rating and seven have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $32.19.
In other Myriad Genetics news, CFO James Evans sold 8,072 shares of the stock on the open market in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $26.50, for a total transaction of $213,908.00. Following the sale, the chief financial officer now directly owns 47,177 shares of the company’s stock, valued at approximately $1,250,191. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Myriad Genetics, Inc (NASDAQ:MYGN) is a molecular diagnostic company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.